The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
MSN Anti‐Cancer Nanomedicines: Chemotherapy Enhancement, Overcoming of Drug Resistance, and Metastasis Inhibition
Abstract
In the anti‐cancer war, there are three main obstacles resulting in high mortality and recurrence rate of cancers: the severe toxic side effect of anti‐cancer drugs to normal tissues due to the lack of tumor‐selectivity, the multi‐drug resistance (MDR) to free chemotherapeutic drugs and the deadly metastases of cancer cells. The development of state‐of‐art nanomedicines based on mesoporous silica nanoparticles (MSNs) is expected to overcome the above three main obstacles. In the view of the fast development of anti‐cancer strategy, this review highlights the most recent advances of MSN anti‐cancer nanomedicines in enhancing chemotherapeutic efficacy, overcoming the MDR and inhibiting metastasis. Furthermore, we give an outlook of the future development of MSNs‐based anti‐cancer nanomedicines, and propose several innovative and forward‐looking anti‐cancer strategies, including tumor tissue−cell−nuclear successionally targeted drug delivery strategy, tumor cell‐selective nuclear‐targeted drug delivery strategy, multi‐targeting and multi‐drug strategy, chemo‐/radio‐/photodynamic‐/ultrasound‐/thermo‐combined multi‐modal therapy by virtue of functionalized hollow/rattle‐structured MSNs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Enzyme-responsive nanoparticles for drug release and diagnostics
de la Rica, R., Aili, D., & Stevens, M. M. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.01.002 · Cited by 765
New developments in ordered mesoporous materials for drug delivery
Manzano, M., & Vallet-Regí, M. (2010) · Journal of Materials Chemistry · doi:10.1039/b922651f · Cited by 359
Photo-Driven Expulsion of Molecules from Mesostructured Silica Nanoparticles
Angelos, S., Choi, E., Vögtle, F., De Cola, L., & Zink, J. I. (2007) · The Journal of Physical Chemistry C · doi:10.1021/jp070721l · Cited by 227
Cited by
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403036 · Cited by 2,164
Gold Nanomaterials at Work in Biomedicine
Yang, X., Yang, M., Pang, B., Vara, M., & Xia, Y. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00193 · Cited by 1,162
Croissant, J. G., Fatieiev, Y., Almalik, A., & Khashab, N. M. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201700831 · Cited by 594
Mesoporous Silica Nanoparticles for Drug Delivery: Current Insights
Vallet-Regí, M., Colilla, M., Izquierdo-Barba, I., & Manzano, M. (2017) · Molecules · doi:10.3390/molecules23010047 · Cited by 538
Manganese Oxide Nanomaterials: Synthesis, Properties, and Theranostic Applications
Ding, B., Zheng, P., Ma, P., & Lin, J. (2020) · Advanced Materials · doi:10.1002/adma.201905823 · Cited by 521
Metadata
- Authors
- He, Q., & Shi, J.
- Venue
- Advanced Materials
- Publisher
- Wiley
- Published
- 2013-10-20
- Volume
- 26
- Issue
- 3
- Pages
- 391-411
- ISSN
- 0935-9648 (ISSN-L)
- 1521-4095
- OpenAlex
- W2048735112
- Cited by
- 482
- References
- 3
- FWCI
- 15.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MSN Anti‐Cancer Nanomedicines: Chemotherapy Enhancement, Overcoming of Drug Resistance, and Metastasis Inhibition. https://app.cochat.ai/papers/10.1002/adma.201303123
- The paper
- He, Q., & Shi, J. (2014). MSN Anti‐Cancer Nanomedicines: Chemotherapy Enhancement, Overcoming of Drug Resistance, and Metastasis Inhibition. Advanced Materials. https://doi.org/10.1002/adma.201303123
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
